Showing results (221-230 of 586) with videos related to
Sort By:
Pageof 59
Journal of the American College of Cardiology|September 5, 2006
Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkersCynthia M Westerhout, Yuling Fu, Michael S Lauer, et al.American Heart Journal|July 24, 2007
No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trialCynthia M Westerhout, Judy Gnarpe, Wei-Ching Chang, et al.Journal of the American Medical Informatics Association : JAMIA|September 13, 2013
A comparison of phenotype definitions for diabetes mellitusRachel L Richesson, Shelley A Rusincovitch, Douglas Wixted, et al.Journal of Thrombosis and Thrombolysis|April 26, 2003
The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIbMichael S Lee, Andreas U Wali, Venu Menon, et al.European Journal of Heart Failure|May 30, 2002
Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failureMonica R Shah, Vic Hasselblad, Sandra S Stinnett, et al.American Heart Journal|February 26, 2008
Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issuesE Marc Jolicoeur, E Magnus Ohman, Robert Temple, et al.Cardiology|February 5, 2003
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy)Arno Breeman, Nestor Mercado, Mattie Lenzen, et al.Cardiovascular Therapeutics|February 27, 2010
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trialsHenry Krum, John J V McMurray, Edward Horton, et al.Circulation|June 10, 2009
Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarctionMark Y Chan, Jie L Sun, L Kristin Newby, et al.European Heart Journal. Digital Health|January 30, 2023
Mapping and quantification of the twitter footprint of cardiologistsAnkur Kalra, Ashish Kumar, Amy S Nowacki, et al.Pageof 59